Search 

The Science Entrepreneur Club (SEC) is a London based non-profit organisation of curious minds that aims to explore and unite the life science ecosystem by educating, inspiring and connecting. We give scientists, innovators and startups, with a focus on biotech, pharma, medtech, bioengineering, biosustainability or related, a network and a unique platform to showcase their innovative technologies, find investors, meet like-minded people and accelerate their company.

Scitribe is a boutique strategic communications consultancy focused on science and technology, including profile-raising, writing and research. It combines professional corporate and scientific communications expertise with lab-based research experience.

Driven by deep understanding and enthusiasm, it applies strategic thinking and listening, combined with a roll-up-your-sleeves & "get it done" know-how, to deliver real value-add output that helps organisations achieve their business and communications objectives.

We apply big-picture thinking and specialist insights to develop strategies that effectively communicate organisations’ impact while ensuring the accurate translation of science for all target audiences and stakeholders. Scitribe provides bespoke, focused and flexible support to provide the clarity, focus, and style that effectively tells our clients’ story through the right channels, to the right audiences.

BioProduction by Sekisui offers contract development and manufacturing services for the biopharmaceutical industry.  Our facility in the UK has over 40 years of fermentation and purification experience with enzymes and proteins as our focus.  We offer expertise in bioprocess development, scale up and manufacturing of enzymes, plasmids, antibody fragments and other proteins.  We offer ISO 9001, ISO 13485 and GMP manufacturing quality standards for your custom production.  We are in the process of a $19M expansion of our GMP facility for drug substance manufacturing which will complete in 2023.

We create robust formulation development strategies tailored to the characteristics of each individual API. We complement the drug discovery process with clearly set-out costs for specific stages, totally transparent from the preclinical stage, formulation, dosage form development and optimisation.

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

We are Simbec-Orion, who for almost five decades, have been providing clinical trial management services across a wide range of therapeutic indications and phases. The clinical research organisation with a flexible, specialist approach, we strive to become a trusted partner for our clients. Our passion as a CRO is rare diseases and oncology.

Sphere Fluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.

Specialities
Biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells

Stratagem's "Strategically Different" approach delivers:
• An out-sourced, total intellectual property management solution.
• An investible patent strategy and maximised value of intellectual property.
• Hands-on management of the creation, maintenance, defence, commercialization, and enforcement of IP rights.
• A proven strategic approach to securing freedom to commercialise and competitive advantage.
Services For BioPartner Members:
• Free 30-minute initial consultation for IP-related matters
• IP overview training sessions for entire companies or select groups e.g. managers or inventors
• Contributions towards presentations, panel discussions, and/or Q&A sessions.

Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facilities in Nottingham and Alderley Park, UK housing over 500 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.

TheraCryf is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. 

There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. 

TheraCryf exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.